MedPath

SKYE BIOSCIENCE INC

SKYE BIOSCIENCE INC logo
🇺🇸United States
Ownership
Public
Established
2012-01-01
Employees
11
Market Cap
$188M
Website
http://skyebioscience.com
Introduction

Skye Bioscience, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new medicines that unlock the pharmaceutical potential of the endocannabinoid system to treat diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration. Its products include nimacimab and SBI-100 Ophthalmic Emulsion. The company was founded on March 16, 2011 and is headquartered in San Diego, CA.

Study to Evaluate the Effect on Obesity of Once Weekly Nimacimab Injection and Once Weekly Nimacimab Injection Co-administered With Semaglutide Injection Versus Placebo

Phase 2
Recruiting
Conditions
Obesity
Interventions
First Posted Date
2024-08-29
Last Posted Date
2024-11-22
Lead Sponsor
Skye Bioscience, Inc.
Target Recruit Count
120
Registration Number
NCT06577090
Locations
🇺🇸

Pinnacle Research Group, Anniston, Alabama, United States

🇺🇸

Diablo Clinical Research, Inc., Walnut Creek, California, United States

🇺🇸

Chase Medical Research, LLC, Waterbury, Connecticut, United States

and more 14 locations

Phase 2, Placebo-Controlled, Study Assessing the Safety and Ocular Efficacy of SBI-100 Ophthalmic Emulsion in Patients With Elevated Eye Pressure

Phase 2
Completed
Conditions
Primary Open Angle Glaucoma
Ocular Hypertension
Interventions
Drug: SBI-100 Ophthalmic Emulsion, 0.5%
Drug: SBI-100 Ophthalmic Emulsion, Placebo
Drug: SBI-100 Ophthalmic Emulsion, 1.0%
First Posted Date
2023-11-22
Last Posted Date
2024-03-15
Lead Sponsor
Skye Bioscience, Inc.
Target Recruit Count
56
Registration Number
NCT06144918
Locations
🇺🇸

Eye Research Foundation, Newport Beach, California, United States

🇺🇸

Global Research Management, Inc., Glendale, California, United States

🇺🇸

Scott & Christie and Associates, PC, Cranberry Township, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath